Paul J. Orchard
Distinguished in Leukodystrophy

Dr. Paul J. Orchard

Pediatric Hematology Oncology
Center For Pediatric Blood And Marrow Transplantation - Pediatric Specialty Care Journey Clinic
2450 Riverside Ave, 
Minneapolis, MN 
Clinical Trials:Currently Recruiting for 1 Trial
37 Years of Experience
Distinguished in Leukodystrophy
Center For Pediatric Blood And Marrow Transplantation - Pediatric Specialty Care Journey Clinic
2450 Riverside Ave, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Orchard is a Pediatric Hematologist Oncologist and a Pediatrics specialist in Minneapolis, Minnesota. He has been an author on 166 peer reviewed articles and participated in 18 clinical trials in the past 15 years. He is licensed to treat patients in MN.

Dr. Orchard is rated as a Distinguished provider by MediFind in the treatment of Leukodystrophy. His top areas of expertise are Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Bone Marrow Transplant, and Osteotomy.

His clinical research consists of co-authoring 205 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Leukodystrophy.

Residency
University of Wisconsin Hospital
Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MN
Board Certifications
Pediatrics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO

Locations

Center for Pediatric Blood and Marrow Transplantation - Pediatric Specialty Care Journey Clinic
2450 Riverside Ave, Minneapolis, MN 55454

Additional Areas of Focus

Dr. Orchard has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
Enrollment Status: Recruiting
Publish Date: August 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Fludarabine, Busulfan, Anti-Thymocyte Globulin, Thiotepa, Rituximab, Alemtuzumab, N-Acetylcysteine, Celecoxib, Vitamin E, Alpha Lipoic Acid
Study Phase: Phase 2
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Enrollment Status: Terminated
Publish Date: March 03, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Genetic
Study Drug: Elivaldogene Autotemcel
Study Phase: Phase 3
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Genetic
Study Phase: Phase 2/Phase 3
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
Enrollment Status: Terminated
Publish Date: May 21, 2020
Intervention Type: Genetic
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
Enrollment Status: Terminated
Publish Date: September 27, 2018
Intervention Type: Drug
Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy
Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy
Enrollment Status: Withdrawn
Publish Date: July 06, 2018
View 6 Less Clinical Trials

205 Total Publications

Neurofilament light chain as a prognostic marker in cerebral adrenoleukodystrophy.
Neurofilament light chain as a prognostic marker in cerebral adrenoleukodystrophy.
Journal: Brain : a journal of neurology
Published: May 01, 2025
Similar Doctors
Advanced in Leukodystrophy
Dr. Troy C. Lund
Pediatric Hematology Oncology
Advanced in Leukodystrophy
Dr. Troy C. Lund
Pediatric Hematology Oncology

Fairview Express Care

2450 Riverside Ave, 
Minneapolis, MN 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances

Troy Lund is a Pediatric Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Lund is rated as a Distinguished provider by MediFind in the treatment of Leukodystrophy. His top areas of expertise are Adrenoleukodystrophy (ALD), Alpha Mannosidosis, Glucose-6-Phosphate Dehydrogenase Deficiency, Aspartylglucosaminuria, and Bone Marrow Transplant.

Experienced in Leukodystrophy
Dr. Jakub Tolar
Pediatric Hematology Oncology
Experienced in Leukodystrophy
Dr. Jakub Tolar
Pediatric Hematology Oncology
516 Delaware Street Se, Pwb 5th Floor, Ste 5-100 Clinic 5b, 
Minneapolis, MN 
 (0.5 miles away)
612-273-2800
Languages Spoken:
English
See accepted insurances

Jakub Tolar is a Pediatric Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Tolar is rated as a Distinguished provider by MediFind in the treatment of Leukodystrophy. His top areas of expertise are Dyskeratosis Congenita, Fanconi Anemia, Congenital Aplastic Anemia, Bone Marrow Transplant, and Osteotomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orchard's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile